-
1
-
-
0030749321
-
Skeletal complications of malignancy
-
Coleman R.E. Skeletal complications of malignancy. Cancer 1997, 80:1588-1594.
-
(1997)
Cancer
, vol.80
, pp. 1588-1594
-
-
Coleman, R.E.1
-
2
-
-
0027257608
-
The bone marrow of MM patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell
-
Billadeau D., Ahmann G., Greipp P., et al. The bone marrow of MM patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993, 178:1023-1031.
-
(1993)
J Exp Med
, vol.178
, pp. 1023-1031
-
-
Billadeau, D.1
Ahmann, G.2
Greipp, P.3
-
3
-
-
1542283717
-
Characterization of clonogenic multiple myeloma cells
-
Matsui W., HuffC.A., Wang Q., et al. Characterization of clonogenic multiple myeloma cells. Blood 2004, 103:2332-2336.
-
(2004)
Blood
, vol.103
, pp. 2332-2336
-
-
Matsui, W.1
Huff, C.A.2
Wang, Q.3
-
5
-
-
0033888977
-
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo
-
Lacey D.L., Tan H.L., Lu J., et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000, 157:435-448.
-
(2000)
Am J Pathol
, vol.157
, pp. 435-448
-
-
Lacey, D.L.1
Tan, H.L.2
Lu, J.3
-
6
-
-
0031005576
-
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density
-
Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
-
(1997)
Cell
, vol.89
, pp. 309-319
-
-
Simonet, W.S.1
Lacey, D.L.2
Dunstan, C.R.3
-
7
-
-
0009660825
-
Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
-
Yasuda H., Shima N., Nakagawa N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139:1329-1337.
-
(1998)
Endocrinology
, vol.139
, pp. 1329-1337
-
-
Yasuda, H.1
Shima, N.2
Nakagawa, N.3
-
8
-
-
0032540319
-
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
-
Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
-
(1998)
Cell
, vol.93
, pp. 165-176
-
-
Lacey, D.L.1
Timms, E.2
Tan, H.L.3
-
9
-
-
0034947297
-
Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells
-
Choi Y., Woo K.M., Ko S.H., et al. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. Eur J Immunol 2001, 31:2179-2188.
-
(2001)
Eur J Immunol
, vol.31
, pp. 2179-2188
-
-
Choi, Y.1
Woo, K.M.2
Ko, S.H.3
-
10
-
-
9444231136
-
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction
-
Colucci S., Brunetti G., Rizzi R., et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004, 104:3722-3730.
-
(2004)
Blood
, vol.104
, pp. 3722-3730
-
-
Colucci, S.1
Brunetti, G.2
Rizzi, R.3
-
11
-
-
10044225587
-
Postmenopausal osteoporosis, T cells, and immune dysfunction
-
Teitelbaum S.L. Postmenopausal osteoporosis, T cells, and immune dysfunction. Proc Natl Acad Sci USA 2004, 101:16711-16712.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 16711-16712
-
-
Teitelbaum, S.L.1
-
12
-
-
0037388342
-
T cells regulate the expression of matrix metalloproteinase in human osteoblasts via a dual mitogen-activated protein kinase mechanism
-
Rifas L., Arackal S. T cells regulate the expression of matrix metalloproteinase in human osteoblasts via a dual mitogen-activated protein kinase mechanism. Arthritis Rheum 2003, 48:993-1001.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 993-1001
-
-
Rifas, L.1
Arackal, S.2
-
13
-
-
0034667933
-
Depletion of CD4 and CD8T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis
-
Grcevic D., Lee S.K., Marusic A., et al. Depletion of CD4 and CD8T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis. J Immunol 2000, 165:4231-4238.
-
(2000)
J Immunol
, vol.165
, pp. 4231-4238
-
-
Grcevic, D.1
Lee, S.K.2
Marusic, A.3
-
15
-
-
0035139583
-
T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms
-
Weitzmann M.N., Cenci S., Rifas L., et al. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res 2001, 16:328-337.
-
(2001)
J Bone Miner Res
, vol.16
, pp. 328-337
-
-
Weitzmann, M.N.1
Cenci, S.2
Rifas, L.3
-
16
-
-
0033581952
-
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
-
Kong Y.Y., Feige U., Sarosi I., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
-
(1999)
Nature
, vol.402
, pp. 304-309
-
-
Kong, Y.Y.1
Feige, U.2
Sarosi, I.3
-
17
-
-
0033805254
-
Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection
-
Teng Y.T., Nguyen H., Gao X., et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000, 106:R59-R67.
-
(2000)
J Clin Invest
, vol.106
-
-
Teng, Y.T.1
Nguyen, H.2
Gao, X.3
-
18
-
-
0034735773
-
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ
-
Takayanagi H., Ogasawara K., Hida S., et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 2000, 408:600-605.
-
(2000)
Nature
, vol.408
, pp. 600-605
-
-
Takayanagi, H.1
Ogasawara, K.2
Hida, S.3
-
19
-
-
14644439140
-
Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis
-
D'Amelio P., Grimaldi A., Pescarmona G.P., et al. Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis. FASEB J 2005, 19:410-412.
-
(2005)
FASEB J
, vol.19
, pp. 410-412
-
-
D'Amelio, P.1
Grimaldi, A.2
Pescarmona, G.P.3
-
20
-
-
13244273716
-
Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement
-
Roato I., Grano M., Brunetti G., et al. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J 2005, 19:228-230.
-
(2005)
FASEB J
, vol.19
, pp. 228-230
-
-
Roato, I.1
Grano, M.2
Brunetti, G.3
-
21
-
-
14444272043
-
TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
-
Wong B.R., Rho J., Arron J., et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997, 272:25190-25194.
-
(1997)
J Biol Chem
, vol.272
, pp. 25190-25194
-
-
Wong, B.R.1
Rho, J.2
Arron, J.3
-
22
-
-
0037148508
-
A novel member of the leukocyte receptor complex regulates osteoclast differentiation
-
Kim N., Takami M., Rho J., et al. A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med 2002, 195:201-209.
-
(2002)
J Exp Med
, vol.195
, pp. 201-209
-
-
Kim, N.1
Takami, M.2
Rho, J.3
-
23
-
-
0033611467
-
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
-
Kong Y.Y., Yoshida H., Sarosi I., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
-
(1999)
Nature
, vol.397
, pp. 315-323
-
-
Kong, Y.Y.1
Yoshida, H.2
Sarosi, I.3
-
24
-
-
0033561039
-
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
-
Lomaga M.A., Yeh W.C., Sarosi I., et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999, 13:1015-1024.
-
(1999)
Genes Dev
, vol.13
, pp. 1015-1024
-
-
Lomaga, M.A.1
Yeh, W.C.2
Sarosi, I.3
-
25
-
-
34247581650
-
Signaling crosstalk between RANKL and interferons in osteoclast differentiation
-
Takayanagi H., Kim S., Taniguchi T. Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res 2002, 4:S227-S232.
-
(2002)
Arthritis Res
, vol.4
-
-
Takayanagi, H.1
Kim, S.2
Taniguchi, T.3
-
26
-
-
0037079719
-
Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells
-
Nosaka K., Miyamoto T., Sakai T., et al. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 2002, 99:634-640.
-
(2002)
Blood
, vol.99
, pp. 634-640
-
-
Nosaka, K.1
Miyamoto, T.2
Sakai, T.3
-
27
-
-
0037114636
-
Human myeloma cells stimulate the receptor activator of nuclear factor-βappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease
-
Giuliani N., Colla S., Sala R., et al. Human myeloma cells stimulate the receptor activator of nuclear factor-βappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002, 100:4615-4621.
-
(2002)
Blood
, vol.100
, pp. 4615-4621
-
-
Giuliani, N.1
Colla, S.2
Sala, R.3
-
28
-
-
0035895083
-
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment
-
Giuliani N., Bataille R., Mancini C., et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001, 98:3527-3533.
-
(2001)
Blood
, vol.98
, pp. 3527-3533
-
-
Giuliani, N.1
Bataille, R.2
Mancini, C.3
-
29
-
-
0035949510
-
Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
-
Pearse R.N., Sordillo E.M., Yaccoby S., et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001, 98:11581-11586.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 11581-11586
-
-
Pearse, R.N.1
Sordillo, E.M.2
Yaccoby, S.3
-
30
-
-
47249140444
-
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
-
Qiang Y.W., Chen Y., Stephens O., et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008, 112:196-207.
-
(2008)
Blood
, vol.112
, pp. 196-207
-
-
Qiang, Y.W.1
Chen, Y.2
Stephens, O.3
-
31
-
-
0037108435
-
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells
-
Standal T., Seidel C., Hjertner O., et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002, 100:3002-3007.
-
(2002)
Blood
, vol.100
, pp. 3002-3007
-
-
Standal, T.1
Seidel, C.2
Hjertner, O.3
-
32
-
-
0037389602
-
Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma
-
Heider U., Langelotz C., Jakob C., et al. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003, 9:1436-1440.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1436-1440
-
-
Heider, U.1
Langelotz, C.2
Jakob, C.3
-
33
-
-
0036140071
-
Human bone marrow myeloma cells express RANKL
-
Sezer O., Heider U., Jakob C., et al. Human bone marrow myeloma cells express RANKL. J Clin Oncol 2002, 20:353-354.
-
(2002)
J Clin Oncol
, vol.20
, pp. 353-354
-
-
Sezer, O.1
Heider, U.2
Jakob, C.3
-
34
-
-
0037097587
-
Immunocytochemistry reveals RANKL expression of myeloma cells
-
Sezer O., Heider U., Jakob C., et al. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 2002, 99:4646-4647.
-
(2002)
Blood
, vol.99
, pp. 4646-4647
-
-
Sezer, O.1
Heider, U.2
Jakob, C.3
-
35
-
-
0035895055
-
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
-
Croucher P.I., Shipman C.M., Lippitt J., et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001, 98:3534-3540.
-
(2001)
Blood
, vol.98
, pp. 3534-3540
-
-
Croucher, P.I.1
Shipman, C.M.2
Lippitt, J.3
-
36
-
-
0036223310
-
RANK (receptor activator of nuclear factor-βappaB) and RANKL expression in multiple myeloma
-
Roux S., Meignin V., Quillard J., et al. RANK (receptor activator of nuclear factor-βappaB) and RANKL expression in multiple myeloma. Br J Haematol 2002, 117:86-92.
-
(2002)
Br J Haematol
, vol.117
, pp. 86-92
-
-
Roux, S.1
Meignin, V.2
Quillard, J.3
-
37
-
-
7344233085
-
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
-
Emery J.G., McDonnell P., Burke M.B., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273:14363-14367.
-
(1998)
J Biol Chem
, vol.273
, pp. 14363-14367
-
-
Emery, J.G.1
McDonnell, P.2
Burke, M.B.3
-
38
-
-
0037086077
-
Osteoprotegerin is a survival factor for human prostate cancer cell
-
Holen I., Croucher P.I., Hamdy F.C., et al. Osteoprotegerin is a survival factor for human prostate cancer cell. Cancer Res 2002, 62:1619-1623.
-
(2002)
Cancer Res
, vol.62
, pp. 1619-1623
-
-
Holen, I.1
Croucher, P.I.2
Hamdy, F.C.3
-
39
-
-
0037374460
-
Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-βelated apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells
-
Shipman C.M., Croucher P.I. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-βelated apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003, 63:912-916.
-
(2003)
Cancer Res
, vol.63
, pp. 912-916
-
-
Shipman, C.M.1
Croucher, P.I.2
-
40
-
-
0034735773
-
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ
-
Takayanagi H., Ogasawara K., Hida S., et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 2000, 408:600-605.
-
(2000)
Nature
, vol.408
, pp. 600-605
-
-
Takayanagi, H.1
Ogasawara, K.2
Hida, S.3
-
41
-
-
0025348745
-
How important are T cells in chronic rheumatoid synovitis?
-
Firestein G.S., Zvaifler N.J. How important are T cells in chronic rheumatoid synovitis?. Arthritis Rheum 1990, 33:768-773.
-
(1990)
Arthritis Rheum
, vol.33
, pp. 768-773
-
-
Firestein, G.S.1
Zvaifler, N.J.2
-
42
-
-
0030951777
-
T-cells in the pathogenesis of rheumatoid arthritis villains or accomplices?
-
Kinne R.W., Palombo-Kinne E., Emmrich F. T-cells in the pathogenesis of rheumatoid arthritis villains or accomplices?. Biochim Biophys Acta 1997, 1360:109-141.
-
(1997)
Biochim Biophys Acta
, vol.1360
, pp. 109-141
-
-
Kinne, R.W.1
Palombo-Kinne, E.2
Emmrich, F.3
-
43
-
-
0034284296
-
Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines
-
Weitzmann M.N., Cenci S., Rifas L., et al. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood 2000, 96:1873-1878.
-
(2000)
Blood
, vol.96
, pp. 1873-1878
-
-
Weitzmann, M.N.1
Cenci, S.2
Rifas, L.3
-
44
-
-
0037422560
-
IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells
-
Toraldo G., Roggia C., Qian W.P., et al. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA 2003, 100:125-130.
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, pp. 125-130
-
-
Toraldo, G.1
Roggia, C.2
Qian, W.P.3
-
45
-
-
0037103193
-
Functional interleukin-7 receptors (IL-7Rs) are expressed by marrow stromal cells: binding of IL-7 increases levels of IL-6 mRNA and secreted protein
-
Iwata M., Graf L., Awaya N., et al. Functional interleukin-7 receptors (IL-7Rs) are expressed by marrow stromal cells: binding of IL-7 increases levels of IL-6 mRNA and secreted protein. Blood 2002, 100:1318-1325.
-
(2002)
Blood
, vol.100
, pp. 1318-1325
-
-
Iwata, M.1
Graf, L.2
Awaya, N.3
-
46
-
-
0025313227
-
IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release
-
Iwata M., Graf L., Awaya N., et al. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 1990, 144:4226-4230.
-
(1990)
J Immunol
, vol.144
, pp. 4226-4230
-
-
Iwata, M.1
Graf, L.2
Awaya, N.3
-
47
-
-
0025896935
-
Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice
-
Black K., Garrett I.R., Mundy G.R. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology 1991, 128:2657-2659.
-
(1991)
Endocrinology
, vol.128
, pp. 2657-2659
-
-
Black, K.1
Garrett, I.R.2
Mundy, G.R.3
-
48
-
-
0029051328
-
Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo
-
De La Mata J., Uy H.L., Guise T.A., et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995, 95:2846-2852.
-
(1995)
J Clin Invest
, vol.95
, pp. 2846-2852
-
-
De La Mata, J.1
Uy, H.L.2
Guise, T.A.3
-
49
-
-
0031895576
-
IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures
-
Devlin R.D., Reddy S.V., Savano R., et al. IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. J Bone Miner Res 1998, 13:393-399.
-
(1998)
J Bone Miner Res
, vol.13
, pp. 393-399
-
-
Devlin, R.D.1
Reddy, S.V.2
Savano, R.3
-
51
-
-
0026505832
-
Myeloma phenotype: clues to disease origin and manifestation
-
Epstein J. Myeloma phenotype: clues to disease origin and manifestation. Hematol Oncol Clin North Am 1992, 6:249-256.
-
(1992)
Hematol Oncol Clin North Am
, vol.6
, pp. 249-256
-
-
Epstein, J.1
-
52
-
-
0033210336
-
Clinical significance of interleukin-6 gene expression in the bone marrow of patients with multiple myeloma
-
Iwasaki T., Hamano T., Ogata A., et al. Clinical significance of interleukin-6 gene expression in the bone marrow of patients with multiple myeloma. Int J Hematol 1999, 70:163-168.
-
(1999)
Int J Hematol
, vol.70
, pp. 163-168
-
-
Iwasaki, T.1
Hamano, T.2
Ogata, A.3
-
53
-
-
0028267592
-
High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma
-
Ballester O.F., Moscinski L.C., Lyman G.H., et al. High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood 1994, 83:1903-1908.
-
(1994)
Blood
, vol.83
, pp. 1903-1908
-
-
Ballester, O.F.1
Moscinski, L.C.2
Lyman, G.H.3
-
54
-
-
0031810469
-
Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance
-
Sati H.I., Apperley J.F., Greaves M., et al. Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Br J Haematol 1998, 101:287-295.
-
(1998)
Br J Haematol
, vol.101
, pp. 287-295
-
-
Sati, H.I.1
Apperley, J.F.2
Greaves, M.3
-
55
-
-
0030889389
-
Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma
-
Teoh G., Anderson K.C. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 1997, 11:27-42.
-
(1997)
Hematol Oncol Clin North Am
, vol.11
, pp. 27-42
-
-
Teoh, G.1
Anderson, K.C.2
-
56
-
-
0032450975
-
Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma
-
Thomas X., Anglaret B., Magaud J.P., Epstein J., et al. Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma. Leuk Lymphoma 1998, 32:107-119.
-
(1998)
Leuk Lymphoma
, vol.32
, pp. 107-119
-
-
Thomas, X.1
Anglaret, B.2
Magaud, J.P.3
Epstein, J.4
-
57
-
-
0034012201
-
Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts
-
Karadag A., Oyajobi B.O., Apperley J.F., et al. Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts. Br J Haematol 2000, 108:383-390.
-
(2000)
Br J Haematol
, vol.108
, pp. 383-390
-
-
Karadag, A.1
Oyajobi, B.O.2
Apperley, J.F.3
-
58
-
-
4944230728
-
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
-
Abe M., Hiura K., Wilde J., et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004, 104:2484-2491.
-
(2004)
Blood
, vol.104
, pp. 2484-2491
-
-
Abe, M.1
Hiura, K.2
Wilde, J.3
-
59
-
-
0024391288
-
Response patterns of purified myeloma cells to hematopoietic growth factors
-
Anderson K., Jones R.M., Morimoto C., et al. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989, 73:1915-1924.
-
(1989)
Blood
, vol.73
, pp. 1915-1924
-
-
Anderson, K.1
Jones, R.M.2
Morimoto, C.3
-
60
-
-
0025313227
-
IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release
-
Kurihara N., Bertolini D., Suda T., et al. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 1990, 144:4226-4230.
-
(1990)
J Immunol
, vol.144
, pp. 4226-4230
-
-
Kurihara, N.1
Bertolini, D.2
Suda, T.3
-
61
-
-
0027405780
-
Cytokines involved in the progression of multiple myeloma
-
Merico F., Bergui L., Gregoretti M.G., et al. Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol 1993, 92:27-31.
-
(1993)
Clin Exp Immunol
, vol.92
, pp. 27-31
-
-
Merico, F.1
Bergui, L.2
Gregoretti, M.G.3
-
62
-
-
30444432403
-
Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients
-
Giuliani N., Morandi F., Tagliaferri S., et al. Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Blood 2006, 107:841-842.
-
(2006)
Blood
, vol.107
, pp. 841-842
-
-
Giuliani, N.1
Morandi, F.2
Tagliaferri, S.3
-
63
-
-
1542313900
-
IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells
-
Lee J.W., Chung H.Y., Ehrlich L.A., et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004, 103:2308-2315.
-
(2004)
Blood
, vol.103
, pp. 2308-2315
-
-
Lee, J.W.1
Chung, H.Y.2
Ehrlich, L.A.3
-
64
-
-
0024326940
-
IL-3 induces differentiation of bone marrow precursor cells to osteoclast-like cells
-
Barton B.E., Mayer R. IL-3 induces differentiation of bone marrow precursor cells to osteoclast-like cells. J Immunol 1989, 143:3211-3216.
-
(1989)
J Immunol
, vol.143
, pp. 3211-3216
-
-
Barton, B.E.1
Mayer, R.2
-
66
-
-
0033403066
-
Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo
-
Randolph G.J., Inaba K., Robbiani D.F., et al. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999, 11:753-761.
-
(1999)
Immunity
, vol.11
, pp. 753-761
-
-
Randolph, G.J.1
Inaba, K.2
Robbiani, D.F.3
-
67
-
-
0037135659
-
The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting
-
Randolph G.J., Sanchez-Schmitz G., Liebman R.M., et al. The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med 2002, 196:517-527.
-
(2002)
J Exp Med
, vol.196
, pp. 517-527
-
-
Randolph, G.J.1
Sanchez-Schmitz, G.2
Liebman, R.M.3
-
68
-
-
0035889132
-
Bifurcation of osteoclasts and dendritic cells from common progenitors
-
Miyamoto T., Ohneda O., Arai F., et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 2001, 98:2544-2554.
-
(2001)
Blood
, vol.98
, pp. 2544-2554
-
-
Miyamoto, T.1
Ohneda, O.2
Arai, F.3
-
69
-
-
10244259169
-
Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment
-
Rivollier A., Mazzorana M., Tebib J., et al. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 2004, 104:4029-4037.
-
(2004)
Blood
, vol.104
, pp. 4029-4037
-
-
Rivollier, A.1
Mazzorana, M.2
Tebib, J.3
-
70
-
-
28544448181
-
Macrophage inflammatory protein-1 may cause reciprocal regulation of osteoclast and dendritic cell differentiation from monocytes in myeloma (abstract)
-
Hashimoto T., Abe M., Tanaka Y., et al. Macrophage inflammatory protein-1 may cause reciprocal regulation of osteoclast and dendritic cell differentiation from monocytes in myeloma (abstract). Haematologica J 2005, 90:46.
-
(2005)
Haematologica J
, vol.90
, pp. 46
-
-
Hashimoto, T.1
Abe, M.2
Tanaka, Y.3
-
71
-
-
0023841073
-
Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties
-
Wolpe S.D., Davatelis G., Sherry B., et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med 1988, 167:570-581.
-
(1988)
J Exp Med
, vol.167
, pp. 570-581
-
-
Wolpe, S.D.1
Davatelis, G.2
Sherry, B.3
-
72
-
-
0030903039
-
Macrophage inflammatory protein-1? (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment
-
Kukita T., Nomiyama H., Ohmoto Y. Macrophage inflammatory protein-1? (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment. Lab Invest 1997, 76:399-406.
-
(1997)
Lab Invest
, vol.76
, pp. 399-406
-
-
Kukita, T.1
Nomiyama, H.2
Ohmoto, Y.3
-
73
-
-
0033608227
-
Macrophage-inflammatory protein-1? regulates preosteoclast differentiation in vitro
-
Scheven B.A., Milne J.S., Hunter I., et al. Macrophage-inflammatory protein-1? regulates preosteoclast differentiation in vitro. Biochem Biophys Res Commun 1999, 254:773-778.
-
(1999)
Biochem Biophys Res Commun
, vol.254
, pp. 773-778
-
-
Scheven, B.A.1
Milne, J.S.2
Hunter, I.3
-
74
-
-
0035383761
-
Macrophage inflammatory protein-1? is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand
-
Han J.H., Choi S.J., Kurihara N., et al. Macrophage inflammatory protein-1? is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001, 97:3349-3353.
-
(2001)
Blood
, vol.97
, pp. 3349-3353
-
-
Han, J.H.1
Choi, S.J.2
Kurihara, N.3
-
75
-
-
0037105599
-
Role for macrophage inflammatory protein (MIP)-1? and MIP-1? in the development of osteolytic lesions in multiple myeloma
-
Abe M., Hiura K., Wilde J., et al. Role for macrophage inflammatory protein (MIP)-1? and MIP-1? in the development of osteolytic lesions in multiple myeloma. Blood 2002, 100:2195-2202.
-
(2002)
Blood
, vol.100
, pp. 2195-2202
-
-
Abe, M.1
Hiura, K.2
Wilde, J.3
-
76
-
-
0342322717
-
Macrophage inflammatory protein-1? is a potential osteoclast stimulatory factor in multiple myeloma
-
Choi S.J., Cruz J.C., Craig F., et al. Macrophage inflammatory protein-1? is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000, 96:671-675.
-
(2000)
Blood
, vol.96
, pp. 671-675
-
-
Choi, S.J.1
Cruz, J.C.2
Craig, F.3
-
77
-
-
0030791806
-
Mechanisms of bone lesions in multiple myeloma and lymphoma
-
Roodman G.D. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1997, 80:1557-1563.
-
(1997)
Cancer
, vol.80
, pp. 1557-1563
-
-
Roodman, G.D.1
-
78
-
-
0037219741
-
Macrophage inflammatory protein-1? is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM
-
Uneda S., Hata H., Matsuno F., et al. Macrophage inflammatory protein-1? is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 2003, 120:53-55.
-
(2003)
Br J Haematol
, vol.120
, pp. 53-55
-
-
Uneda, S.1
Hata, H.2
Matsuno, F.3
-
79
-
-
0141707692
-
Serum levels of macrophage inflammatory protein-1? (MIP-1?) correlate with the extent of bone disease and survival in patients with multiple myeloma
-
Terpos E., Politou M., Szydlo R., et al. Serum levels of macrophage inflammatory protein-1? (MIP-1?) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003, 123:106-109.
-
(2003)
Br J Haematol
, vol.123
, pp. 106-109
-
-
Terpos, E.1
Politou, M.2
Szydlo, R.3
-
80
-
-
10744221725
-
Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease
-
Magrangeas F., Nasser V., Avet-Loiseau H., et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 2003, 101:4998-5006.
-
(2003)
Blood
, vol.101
, pp. 4998-5006
-
-
Magrangeas, F.1
Nasser, V.2
Avet-Loiseau, H.3
-
81
-
-
1842505726
-
Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1? and MIP-1? correlates with lytic bone lesions in patients with multiple myeloma
-
Hashimoto T., Abe M., Oshima T., et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1? and MIP-1? correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 2004, 125:38-41.
-
(2004)
Br J Haematol
, vol.125
, pp. 38-41
-
-
Hashimoto, T.1
Abe, M.2
Oshima, T.3
-
82
-
-
0035664488
-
Antisense inhibition of macrophage inflammatory protein 1-? blocks bone destruction in a model of myeloma bone disease
-
Choi S.J., Oba Y., Gazitt Y., et al. Antisense inhibition of macrophage inflammatory protein 1-? blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001, 108:1833-1841.
-
(2001)
J Clin Invest
, vol.108
, pp. 1833-1841
-
-
Choi, S.J.1
Oba, Y.2
Gazitt, Y.3
-
83
-
-
0038579121
-
Dual effects of macrophage inflammatory protein-1? on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease
-
Oyajobi B.O., Franchin G., Williams P.J., et al. Dual effects of macrophage inflammatory protein-1? on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003, 102:311-319.
-
(2003)
Blood
, vol.102
, pp. 311-319
-
-
Oyajobi, B.O.1
Franchin, G.2
Williams, P.J.3
-
84
-
-
0038042552
-
Pathophysiology of myeloma bone disease
-
Martin Dunitz, London, G.R. Mundy, R.D. Rubens (Eds.)
-
Mundy G.R., Oyajobi B.O. Pathophysiology of myeloma bone disease. Cancer and the Skeleton 2000, 21-32. Martin Dunitz, London. G.R. Mundy, R.D. Rubens (Eds.).
-
(2000)
Cancer and the Skeleton
, pp. 21-32
-
-
Mundy, G.R.1
Oyajobi, B.O.2
-
85
-
-
0036856052
-
Bisphosphonates in cancer therapy
-
Green J.R. Bisphosphonates in cancer therapy. Curr Opin Oncol 2002, 14:609-615.
-
(2002)
Curr Opin Oncol
, vol.14
, pp. 609-615
-
-
Green, J.R.1
-
86
-
-
0036181668
-
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity
-
Yaccoby S., Pearse R.N., Johnson C.L., et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002, 116:278-290.
-
(2002)
Br J Haematol
, vol.116
, pp. 278-290
-
-
Yaccoby, S.1
Pearse, R.N.2
Johnson, C.L.3
-
87
-
-
0037439916
-
Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma
-
Vanderkerken K., De Leenheer E., Shipman C., et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003, 63:287-289.
-
(2003)
Cancer Res
, vol.63
, pp. 287-289
-
-
Vanderkerken, K.1
De Leenheer, E.2
Shipman, C.3
-
88
-
-
0035895055
-
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
-
Croucher P.I., Shipman C.M., Lippitt J., et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001, 98:3534-3540.
-
(2001)
Blood
, vol.98
, pp. 3534-3540
-
-
Croucher, P.I.1
Shipman, C.M.2
Lippitt, J.3
-
89
-
-
0346837985
-
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
-
Body J.J., Greipp P., Coleman R.E., et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003, 97:887-992.
-
(2003)
Cancer
, vol.97
, pp. 887-992
-
-
Body, J.J.1
Greipp, P.2
Coleman, R.E.3
-
90
-
-
33644760436
-
A study of the biological receptor activator of nuclear factor-βappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
-
Body J.J., Facon T., Coleman R.E., et al. A study of the biological receptor activator of nuclear factor-βappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006, 12:1221-1228.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 1221-1228
-
-
Body, J.J.1
Facon, T.2
Coleman, R.E.3
-
92
-
-
0024208591
-
Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein-1?
-
Sherry B., Tekamp-Olson P., Gallegos C., et al. Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein-1?. J Exp Med 1988, 168:2251-2259.
-
(1988)
J Exp Med
, vol.168
, pp. 2251-2259
-
-
Sherry, B.1
Tekamp-Olson, P.2
Gallegos, C.3
|